Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Ig Enhancers Increase RNA Polymerase II Stalling at Somatic Hypermutation Target Sequences

Alina Tarsalainen, Yaakov Maman, Fei-Long Meng, Minna K. Kyläniemi, Anni Soikkeli, Paulina Budzyńska, Jessica J. McDonald, Filip Šenigl, Frederic W. Alt, David G. Schatz and Jukka Alinikula
J Immunol January 1, 2022, 208 (1) 143-154; DOI: https://doi.org/10.4049/jimmunol.2100923
Alina Tarsalainen
*Unit of Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alina Tarsalainen
Yaakov Maman
†The Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fei-Long Meng
‡Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA;
§Department of Genetics, Harvard University, Boston, MA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minna K. Kyläniemi
*Unit of Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Minna K. Kyläniemi
Anni Soikkeli
*Unit of Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulina Budzyńska
*Unit of Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paulina Budzyńska
Jessica J. McDonald
¶Department of Immunobiology, Yale School of Medicine, New Haven, CT; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jessica J. McDonald
Filip Šenigl
‖Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Praha, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederic W. Alt
‡Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA;
§Department of Genetics, Harvard University, Boston, MA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Frederic W. Alt
David G. Schatz
¶Department of Immunobiology, Yale School of Medicine, New Haven, CT; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David G. Schatz
Jukka Alinikula
*Unit of Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jukka Alinikula
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF
Loading

Key Points

  • Ig enhancers (DIVACs) increase RNA Pol II stalling in the SHM target gene.

  • DIVACs do not operate by increasing antisense transcription.

Abstract

Somatic hypermutation (SHM) drives the genetic diversity of Ig genes in activated B cells and supports the generation of Abs with increased affinity for Ag. SHM is targeted to Ig genes by their enhancers (diversification activators [DIVACs]), but how the enhancers mediate this activity is unknown. We show using chicken DT40 B cells that highly active DIVACs increase the phosphorylation of RNA polymerase II (Pol II) and Pol II occupancy in the mutating gene with little or no accompanying increase in elongation-competent Pol II or production of full-length transcripts, indicating accumulation of stalled Pol II. DIVAC has similar effect also in human Ramos Burkitt lymphoma cells. The DIVAC-induced stalling is weakly associated with an increase in the detection of ssDNA bubbles in the mutating target gene. We did not find evidence for antisense transcription, or that DIVAC functions by altering levels of H3K27ac or the histone variant H3.3 in the mutating gene. These findings argue for a connection between Pol II stalling and cis-acting targeting elements in the context of SHM and thus define a mechanistic basis for locus-specific targeting of SHM in the genome. Our results suggest that DIVAC elements render the target gene a suitable platform for AID-mediated mutation without a requirement for increasing transcriptional output.

Footnotes

  • This work was supported by the Israel Science Foundation Grant 1920/20 (Y.M.), Czech Science Foundation Grant 15-24776S (F.S.), National Institutes of Health Grants AI 127642 (D.G.S.) and T32 AI 007019 (J.J.M.), grants from the Sigrid Juselius Foundation, the Jane and Aatos Erkko Foundation, the Jenny and Antti Wihuri Foundation, the Ella and Georg Ehrnrooth Foundation, the Cancer Society of South-West Finland and the Emil Aaltonen Foundation (J.A.), the Turku University Foundation and the Maud Kuistila Memorial Foundation (J.A. and A.S.), as well as the K. Albin Johanssons Foundation (P.B.).

  • The online version of this article contains supplemental material.

  • Abbreviations used in this article

    AID
    activation-induced cytidine deaminase
    ChIP
    chromatin immunoprecipitation
    ChIP-seq
    ChIP-sequencing
    CSR
    class-switch recombination
    DIVAC
    diversification activator
    DSIF
    DRB sensitivity-inducing factor
    GC
    germinal center
    GCV
    gene conversion
    GRO-seq
    global run-on sequencing
    H3K27ac
    histone H3 at lysine 27
    MFI
    mean fluorescence intensity
    NELF
    negative elongation factor
    Pol II
    RNA polymerase II
    qRT-PCR
    quantitative RT–PCR
    Ri
    Rag1 intron
    rpkm
    reads per kb per million reads
    SHM
    somatic hypermutation
    ssC
    single-stranded deoxycytidine
    TAD
    topologically associating domain
    TSS
    transcription start site

  • Received September 23, 2021.
  • Accepted October 20, 2021.
  • Copyright © 2021 by The American Association of Immunologists, Inc.
View Full Text

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Log in using your username and password

Forgot your user name or password?
PreviousNext
Back to top

In this issue

The Journal of Immunology: 208 (1)
The Journal of Immunology
Vol. 208, Issue 1
1 Jan 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Ig Enhancers Increase RNA Polymerase II Stalling at Somatic Hypermutation Target Sequences
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Ig Enhancers Increase RNA Polymerase II Stalling at Somatic Hypermutation Target Sequences
Alina Tarsalainen, Yaakov Maman, Fei-Long Meng, Minna K. Kyläniemi, Anni Soikkeli, Paulina Budzyńska, Jessica J. McDonald, Filip Šenigl, Frederic W. Alt, David G. Schatz, Jukka Alinikula
The Journal of Immunology January 1, 2022, 208 (1) 143-154; DOI: 10.4049/jimmunol.2100923

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Ig Enhancers Increase RNA Polymerase II Stalling at Somatic Hypermutation Target Sequences
Alina Tarsalainen, Yaakov Maman, Fei-Long Meng, Minna K. Kyläniemi, Anni Soikkeli, Paulina Budzyńska, Jessica J. McDonald, Filip Šenigl, Frederic W. Alt, David G. Schatz, Jukka Alinikula
The Journal of Immunology January 1, 2022, 208 (1) 143-154; DOI: 10.4049/jimmunol.2100923
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Poor-Quality Vβ Recombination Signal Sequences and the DNA Damage Response ATM Kinase Collaborate to Establish TCRβ Gene Repertoire and Allelic Exclusion
  • Multifaceted Activities of Seven Nanobodies against Complement C4b
  • Promoter Proximity Defines Mutation Window for VH and VΚ Genes Rearranged to Different J Genes
Show more MOLECULAR AND STRUCTURAL IMMUNOLOGY

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606